名稱 | BCR(E13)-ABL1(E2)_P210 Fusion |
型號(hào) | CBP20207R |
報(bào)價(jià) | ![]() |
特點(diǎn) | BCR(E13)-ABL1(E2)_P210 Fusion |
產(chǎn)品搜索
相關(guān)文章
- 淺談NTRK fusion
- RNA-Fusion Cocktail再升級(jí)
- IDH基因診斷標(biāo)準(zhǔn)品
- 【靶點(diǎn)模型+診斷質(zhì)控】c-Kit常見突變的藥物開發(fā)和診斷
- 泛腫瘤大panel質(zhì)控品升級(jí),免費(fèi)試用申請(qǐng)中
- 人結(jié)腸癌細(xì)胞株的生長(zhǎng)曲線分析
- ATCC細(xì)胞株開發(fā)的四階段簡(jiǎn)介
- 降糖+減肥?GIPR靶點(diǎn)研究進(jìn)展
- 聚焦靶點(diǎn)BRAF——BRAF相關(guān)突變細(xì)胞強(qiáng)勢(shì)登場(chǎng)
- 鑒別出促進(jìn)黑色素瘤進(jìn)展的關(guān)鍵蛋白,開發(fā)出新型癌癥靶向療法
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > Fusion > CBP20207RBCR(E13)-ABL1(E2)_P210 Fusion

- 詳細(xì)內(nèi)容
CBP20207R | |
Format | RNA |
Description | Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. |
Technical Data | |
Left Gene | BCR |
Right Gene | ABL1 |
Left Breakpoint | chr22:23631808:+(hg19) |
Right Breakpoint | chr9:133729451:+(hg19) |
Buffer | Tris-EDTA |
Product Information | |
Intended Use | Research Use Only |
Unit Size | 1ug |
Concentration | Download for COA |
Purity | Download for COA |
RNA electrophoresis | Download for COA |
Sanger sequencing | |
Storage | -80℃ |
Expiry | 12 months from the date of manufacture |